Health Care & Life Sciences » Pharmaceuticals | Shenzhen Salubris Pharmaceuticals Co. Ltd.

Shenzhen Salubris Pharmaceuticals Co. Ltd. | Mutual Funds

Mutual Funds that own Shenzhen Salubris Pharmaceuticals Co. Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Da Cheng Strategy Return Equity Fund
5,397,098
0.52%
1,950,125
6.57%
12/31/2017
4,625,080
0.44%
2,435,300
4.59%
12/31/2017
Da Cheng Jingyang Lingxian Fund
3,755,693
0.36%
-503,119
6.8%
12/31/2017
LC Value Discovery Equity Fund
2,572,934
0.25%
1,073,100
1.37%
12/31/2017
Da Cheng Innovation Growth Fund
2,423,539
0.23%
1,119,416
3.4%
12/31/2017
1,951,880
0.19%
-1,007,521
6.72%
12/31/2017
1,914,931
0.18%
-855,387
4.71%
12/31/2017
lnvesco Great Wall Domestic Demand Growth II Fund
1,229,300
0.12%
1,229,300
2.16%
12/31/2017
Nikko Asset Chinese A Stocks Mother Fund
1,129,964
0.11%
1,129,964
1.94%
10/04/2017
1,078,011
0.1%
668,394
4.32%
12/31/2017

About Shenzhen Salubris Pharmaceuticals Co.

View Profile
Address
37/F, Chegongmiao Lujing Plaza Bldg
Shenzhen Guangdong 518040
China
Employees -
Website http://www.salubris.cn
Updated 07/08/2019
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and biomedical products. It offers cardiovascular drugs and antibiotics, and active pharmaceutical ingredient products. The company was founded on November 3, 1998 and is headquartered in Shenzhen, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.